The promotion of Raj Puri to Chief Regulatory Officer suggests a strategic emphasis on regulatory affairs, which is crucial for the approval and commercialization of Iovance's cancer therapies. This could positively impact the company's ability to bring products to market, potentially boosting investor confidence.